Please assess the completion status of the following clinical trial:

Trial Title: Study of Tirofiban Administration in Patients With Aspirin and or Clopidogrel Resistance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. All Patients older than 18 years scheduled for coronary angiography and/or PCI will be enrolled. \[Patients should be CK-MB negative (to avoid CK washout with revascularization) and also cTnI/T negative whereas other high-risk features will not lead to patient exclusion.~2. All consecutive patients with stable or unstable troponin and CK-MB negative coronary artery disease showing aspirin and or clopidogrel resistance (ACR) will be enrolled. These include:~   * Patients with clinical indication to undergo angiography for possible revascularisation.~  * Patients with ACR in whom catheter-based coronary intervention is planned based on previous angiogram.~Exclusion Criteria:~1. Patients who can not give informed consent or have a life expectancy of \< 1 year~2. Evolving or Ongoing myocardial infarction (MI) (Persistence of or developing Q wave or ST segment elevation at ECG with or without typical chest pain or typical rapid rise and fall CK-MB or new LBBB) or patients in whom the treating physician intends to use a Gp IIB/IIIa inhibitors.~3. Administration of any GP IIb/IIIa receptor antagonist, anticoagulation, or lytic therapy in the previous 30 days~4. Serum creatinine more than 2.5 mg/dl (221 micromol/L)~5. Ongoing bleeding or bleeding diathesis or contraindication for anticoagulation or increase bleeding risk or history of bleeding in the last 1 year~6. Previous stroke or TIA or any intracranial pathology in the last six months~7. Major surgery or trauma within the previous six weeks~8. Platelet count \< 100.000 per cubic mm or HCT ,33% or Hb \< 11 gm/dL~9. Subjects who received low-molecular-weight heparin within the 24 hours prior to randomization~10. Subjects with an allergy or intolerance to aspirin, heparin, clopidogrel, or tirofiban~11. Patients with severe hypertension (SBP \> 180 mm Hg or DBP \> 110 mm Hg) or in cardiogenic shock (SBP 80 mm Hg or below for \> 30 minutes) or requiring IABP

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Aspirin, clopidogrel, Unfractioned heparin or bivalirudin plus tirofiban infusion given at high bolus dose
- 2 (Type: PLACEBO_COMPARATOR): Aspirin, clopidogrel, Unfractioned heparin or bivalirudin plus placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).